Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Guardant Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Guardant Health's regulatory disclosures and financial reporting.
Guardant Health, Inc. Chief Technology Officer Darya Chudova reported a grant of 23,856 restricted stock units. The award was granted on March 11, 2026 and will convert into an equal number of common shares as it vests. According to the vesting schedule, 33% of the units will vest on April 1, 2027, with the remaining 67% vesting in equal quarterly installments over the following two years. After this grant, her reported direct holdings in this award total 23,856 restricted stock units.
Bell Michael Brian reported acquisition or exercise transactions in this Form 4 filing.
Guardant Health, Inc. Chief Financial Officer Michael Brian Bell received a grant of 26,582 restricted stock units on March 11, 2026 as equity compensation. The award vests over three years: 33% on April 1, 2027 and the remaining 67% in equal quarterly installments over the following two years, settling in common stock as units vest.
Guardant Health, Inc. director Manuel Hidalgo Medina reported option exercises and share sales in company stock. On March 6, 2026, he exercised a stock option for 1,000 shares at a price of $0.00 per share, receiving 1,000 shares of common stock valued at $32.55 per share in the transaction record.
The same day, he sold a total of 1,300 shares of common stock in open-market transactions at average prices of $91.6065 and $91.3001 per share, leaving him with 1,193 common shares held directly after the sales. The underlying stock option was originally granted on July 17, 2024 and vests over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years.
Guardant Health insiders reported proposed sales and recent transactions under Form 144. The filing lists restricted stock lapses of 101 shares on 08/17/2025 and 199 shares on 09/17/2025, and a stock option exercise resulting in 1,000 shares on 03/06/2026 (broker payment for cashless exercise). The excerpt also shows a reported sale of 1,250 shares by Manuel Hidalgo Medina on 12/08/2025 for $131,250.
Guardant Health Chief Information Officer Kumud Kalia exercised stock options and sold shares on March 4, 2026. He exercised multiple stock option awards, converting them into common stock at exercise prices including $47.20, $74.00, $32.86, $28.37, and $28.61 per share.
On the same date, he sold a total of 40,000 shares of Guardant Health common stock in open-market transactions at weighted average prices of about $95.12 and $95.73 per share, across ranges disclosed in the footnotes. After these trades, he directly held 37,643 shares of common stock.
The option awards he exercised were originally granted between April 20, 2020 and November 8, 2024 and vest over three- or four-year schedules, with initial portions vesting on specified dates and remaining shares vesting in equal monthly installments thereafter.
Guardant Health, Inc. submitted a Rule 144 notice for the proposed sale of 40,000 common shares on 03/04/2026. The filing lists Charles Schwab & Co., Inc. as the broker and identifies the method as a Broker Payment for Cashless Exercise.
An earlier sale by Kumud Kalia of 2,000 shares on 12/08/2025 for $209,204.00 is reported as securities sold during the past three months.
Guardant Health director Steve E. Krognes reported the vesting and conversion of restricted stock units into common shares. On August 9, 2022 he received a restricted stock unit award that began vesting June 30, 2023, with 25% vesting then and the remaining 75% vesting in equal monthly installments over three years. On February 28, 2026, 154 restricted stock units vested and were converted at no cost into 154 shares of Guardant Health common stock. After these transactions, he directly held 618 restricted stock units and 19,053 shares of common stock.
Guardant Health director Roberto Mignone reported the vesting and settlement of 264 restricted stock units on February 21, 2026. These units, granted on November 8, 2024, convert into common stock at no cost as part of a four-year equity award vesting schedule.
Guardant Health, Inc. files its annual report describing a precision oncology business built around blood and tissue tests, real‑world data and AI analytics to manage cancer across screening, therapy selection and recurrence monitoring. Key products include Guardant360 liquid and tissue tests, Guardant Reveal for minimal residual disease and therapy response, and the Shield blood test for colorectal cancer screening.
The company highlights FDA approvals for Guardant360 CDx and Shield, Medicare coverage for several assays, and expanding global partnerships in Europe and Asia to run its technology locally. Its Smart Platform integrates genomic and epigenomic data to power multiple tests and biopharma offerings. As of the most recent reference dates, non‑affiliate equity market value was about $6.2 billion and common shares outstanding were 131,170,441.
Guardant Health, Inc. reported strong growth for the fourth quarter and full year 2025 while still operating at a sizeable loss. Fourth quarter revenue rose 39% to $281.3 million, with Oncology revenue up 30% to $189.9 million and Screening revenue reaching $35.1 million on about 38,000 Shield tests. Non-GAAP gross margin improved to 66%.
For 2025 as a whole, revenue grew 33% to $982.0 million, driven by Oncology revenue of $683.6 million and Screening revenue of $79.7 million on roughly 87,000 Shield tests. Non-GAAP gross margin increased to 66%, but the company recorded a GAAP net loss of $416.3 million, or $3.32 per share, and a non-GAAP net loss of $228.1 million.
Free cash flow burn improved to $233.1 million from $274.9 million. For 2026, Guardant Health expects revenue between $1.25 billion and $1.28 billion, representing growth of 27% to 30%, with continued expansion in Oncology, Biopharma & Data, and a sharp increase in Screening revenue and test volumes.